Stepwise evolution of therapy resistance in AML

Relapse of AML patients to FLT3i treatment is the result of a long-term and stepwise process leading to resistance, whereby residual cancer cells initially survive and subsequently expand. Here, Joshi et al. use a multi-faceted approach to characterize how microenvironment-driven early resistance to gilteritinib evolves into mutation-driven late resistance.

Automated summary

Relapse of AML patients to FLT3i treatment is a result of a long-term and stepwise process, where residual cancer cells initially survive and subsequently expand due to resistance. Joshi et al. demonstrate that early resistance to gilteritinib, driven by the microenvironment, evolves into mutation-driven late resistance through a multi-faceted approach.